In the largest prospective study to date of PD-1/PD-L1 targeted therapies in PTCL, 102 patients from 41 centers in China were enrolled to receive the anti-PD-1 antibody geptanolimab for R/R PTCL. This evidence concerns the gene CD274 and mature T-cell and NK-cell non-Hodgkin lymphoma.